A phase II, multi-centre, double-blind, placebo-controlled, 2-way cross-over study to evaluate efficacy, plasma concentrations and safety of 0.25 mL of 20 % w/w PSD503 for topical application in female volunteer patients with stress urinary incontinence

Trial Profile

A phase II, multi-centre, double-blind, placebo-controlled, 2-way cross-over study to evaluate efficacy, plasma concentrations and safety of 0.25 mL of 20 % w/w PSD503 for topical application in female volunteer patients with stress urinary incontinence

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2014

At a glance

  • Drugs Phenylephrine (Primary)
  • Indications Stress incontinence
  • Focus Therapeutic Use
  • Sponsors Plethora Solutions
  • Most Recent Events

    • 01 Dec 2011 Results published in the European Journal of Obstetrics and Gynecology and Reproductive Biology.
    • 04 Jun 2010 Results have been presented as a late breaking abstract at the American Urological Association Annual Meeting according to a Plethora Solutions media release.
    • 10 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top